OMER
Omeros CorpPrice & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash and short-term investments | $135.3M | as of March 31, 2026 | — |
| Non-GAAP adjusted net loss non-GAAP | $17.1M | Q1 2026 | — |
| adjusted net loss non-GAAP | $17.1M | first quarter of 2026 call | — |
| adjusted net loss per share non-GAAP | $0.24 | first quarter of 2026 call | — |
| P&T committee approval rate - top 20 centers | 40% | Q1 FY2026 call | — |
| P&T committee approval rate - top 40 centers | 38% | Q1 FY2026 call | — |
| P&T committee approval rate - top 80 U.S. centers | 30% | Q1 FY2026 call | — |
| shares of common stock repurchased and retired | 360,000 | Q1 FY2026 call | — |
| shares repurchased | 360,000 | first quarter of 2026 call | — |
| transplant centers detailed | 175 | Q1 FY2026 call | — |
| unique accounts that had ordered YARTEMLEA | 30 | first quarter of 2026 call | — |
| unique accounts that had ordered Yartemlia | 30 | Q1 FY2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OMER
this stock
Omeros Corp
|
$755.60M | -39.6% | -53.9% | 9.1 | 20.9% |
|
ONC
BeOne Medicines Ltd.
|
$449.85B | +2.5% | +22179.2% | 915.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.09B | +5.2% | +46.2% | 28.3 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.66B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$53.96B | +2.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OMER | +1.3% | +13.1% | -14.2% | +9.0% | -39.6% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | +0.0% | +13.3% | -24.3% | +8.0% | -50.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.